PT  - JOURNAL ARTICLE
AU  - Michael Hafner
AU  - Susanne Paukner
AU  - Wolfgang W. Wicha
AU  - Boška Hrvačić
AU  - Steven P. Gelone
TI  - Anti-inflammatory Activity of Lefamulin in a Lipopolysaccharide-Induced Lung Neutrophilia Model
AID  - 10.1101/2020.06.23.168393
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.06.23.168393
4099  - http://biorxiv.org/content/early/2020/06/26/2020.06.23.168393.short
4100  - http://biorxiv.org/content/early/2020/06/26/2020.06.23.168393.full
AB  - Lefamulin is a novel pleuromutilin antibiotic approved for the treatment of community-acquired bacterial pneumonia. This study demonstrated anti-inflammatory activity of lefamulin in a murine lipopolysaccharide-induced lung neutrophilia model. Pretreatment of mice at clinically relevant lefamulin subcutaneous doses (35, 70, 140 mg/kg [free base]) followed by intranasal lipopolysaccharide challenge (5 μg/50 μL/mouse) demonstrated significant, dose-dependent reductions in total and neutrophil cell counts in bronchoalveolar lavage fluid samples, with reductions comparable to oral dexamethasone (0.5 mg/kg) pretreatment.